Report cover image

Global Biosimilar Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20361075

Description

Summary

According to APO Research, The global Biosimilar market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Biosimilar is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Biosimilar include Bio-Thera, Shanghai Henlius, Gan&Lee, Jiangsu Hengrui, United Laboratory, Luye Pharma, Qilu Pharmaceutical, 3SBIO and Tonghua Dongbao, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Biosimilar, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar, also provides the revenue of main regions and countries. Of the upcoming market potential for Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Biosimilar revenue, projected growth trends, production technology, application and end-user industry.

Biosimilar Segment by Company

Bio-Thera
Shanghai Henlius
Gan&Lee
Jiangsu Hengrui
United Laboratory
Luye Pharma
Qilu Pharmaceutical
3SBIO
Tonghua Dongbao
Innovent Biologics
Zhejiang Hisun
Biosimilar Segment by Type

Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar Segment by Application

Diabetes
Immunological Diseases
Cancer
Others
Biosimilar Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Biosimilar company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Biosimilar Market by Type
1.2.1 Global Biosimilar Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
1.3 Biosimilar Market by Application
1.3.1 Global Biosimilar Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Diabetes
1.3.3 Immunological Diseases
1.3.4 Cancer
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biosimilar Market Dynamics
2.1 Biosimilar Industry Trends
2.2 Biosimilar Industry Drivers
2.3 Biosimilar Industry Opportunities and Challenges
2.4 Biosimilar Industry Restraints
3 Global Growth Perspective
3.1 Global Biosimilar Market Perspective (2020-2031)
3.2 Global Biosimilar Growth Trends by Region
3.2.1 Global Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Biosimilar Market Size by Region (2020-2025)
3.2.3 Global Biosimilar Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Biosimilar Revenue by Players
4.1.1 Global Biosimilar Revenue by Players (2020-2025)
4.1.2 Global Biosimilar Revenue Market Share by Players (2020-2025)
4.1.3 Global Biosimilar Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Biosimilar Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Biosimilar Key Players Headquarters & Area Served
4.4 Global Biosimilar Players, Product Type & Application
4.5 Global Biosimilar Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Biosimilar Market CR5 and HHI
4.6.3 2024 Biosimilar Tier 1, Tier 2, and Tier 3
5 Biosimilar Market Size by Type
5.1 Global Biosimilar Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Biosimilar Revenue by Type (2020-2031)
5.3 Global Biosimilar Revenue Market Share by Type (2020-2031)
6 Biosimilar Market Size by Application
6.1 Global Biosimilar Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Biosimilar Revenue by Application (2020-2031)
6.3 Global Biosimilar Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Bio-Thera
7.1.1 Bio-Thera Comapny Information
7.1.2 Bio-Thera Business Overview
7.1.3 Bio-Thera Biosimilar Revenue and Gross Margin (2020-2025)
7.1.4 Bio-Thera Biosimilar Product Portfolio
7.1.5 Bio-Thera Recent Developments
7.2 Shanghai Henlius
7.2.1 Shanghai Henlius Comapny Information
7.2.2 Shanghai Henlius Business Overview
7.2.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (2020-2025)
7.2.4 Shanghai Henlius Biosimilar Product Portfolio
7.2.5 Shanghai Henlius Recent Developments
7.3 Gan&Lee
7.3.1 Gan&Lee Comapny Information
7.3.2 Gan&Lee Business Overview
7.3.3 Gan&Lee Biosimilar Revenue and Gross Margin (2020-2025)
7.3.4 Gan&Lee Biosimilar Product Portfolio
7.3.5 Gan&Lee Recent Developments
7.4 Jiangsu Hengrui
7.4.1 Jiangsu Hengrui Comapny Information
7.4.2 Jiangsu Hengrui Business Overview
7.4.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (2020-2025)
7.4.4 Jiangsu Hengrui Biosimilar Product Portfolio
7.4.5 Jiangsu Hengrui Recent Developments
7.5 United Laboratory
7.5.1 United Laboratory Comapny Information
7.5.2 United Laboratory Business Overview
7.5.3 United Laboratory Biosimilar Revenue and Gross Margin (2020-2025)
7.5.4 United Laboratory Biosimilar Product Portfolio
7.5.5 United Laboratory Recent Developments
7.6 Luye Pharma
7.6.1 Luye Pharma Comapny Information
7.6.2 Luye Pharma Business Overview
7.6.3 Luye Pharma Biosimilar Revenue and Gross Margin (2020-2025)
7.6.4 Luye Pharma Biosimilar Product Portfolio
7.6.5 Luye Pharma Recent Developments
7.7 Qilu Pharmaceutical
7.7.1 Qilu Pharmaceutical Comapny Information
7.7.2 Qilu Pharmaceutical Business Overview
7.7.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (2020-2025)
7.7.4 Qilu Pharmaceutical Biosimilar Product Portfolio
7.7.5 Qilu Pharmaceutical Recent Developments
7.8 3SBIO
7.8.1 3SBIO Comapny Information
7.8.2 3SBIO Business Overview
7.8.3 3SBIO Biosimilar Revenue and Gross Margin (2020-2025)
7.8.4 3SBIO Biosimilar Product Portfolio
7.8.5 3SBIO Recent Developments
7.9 Tonghua Dongbao
7.9.1 Tonghua Dongbao Comapny Information
7.9.2 Tonghua Dongbao Business Overview
7.9.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (2020-2025)
7.9.4 Tonghua Dongbao Biosimilar Product Portfolio
7.9.5 Tonghua Dongbao Recent Developments
7.10 Innovent Biologics
7.10.1 Innovent Biologics Comapny Information
7.10.2 Innovent Biologics Business Overview
7.10.3 Innovent Biologics Biosimilar Revenue and Gross Margin (2020-2025)
7.10.4 Innovent Biologics Biosimilar Product Portfolio
7.10.5 Innovent Biologics Recent Developments
7.11 Zhejiang Hisun
7.11.1 Zhejiang Hisun Comapny Information
7.11.2 Zhejiang Hisun Business Overview
7.11.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (2020-2025)
7.11.4 Zhejiang Hisun Biosimilar Product Portfolio
7.11.5 Zhejiang Hisun Recent Developments
8 North America
8.1 North America Biosimilar Revenue (2020-2031)
8.2 North America Biosimilar Revenue by Type (2020-2031)
8.2.1 North America Biosimilar Revenue by Type (2020-2025)
8.2.2 North America Biosimilar Revenue by Type (2026-2031)
8.3 North America Biosimilar Revenue Share by Type (2020-2031)
8.4 North America Biosimilar Revenue by Application (2020-2031)
8.4.1 North America Biosimilar Revenue by Application (2020-2025)
8.4.2 North America Biosimilar Revenue by Application (2026-2031)
8.5 North America Biosimilar Revenue Share by Application (2020-2031)
8.6 North America Biosimilar Revenue by Country
8.6.1 North America Biosimilar Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Biosimilar Revenue by Country (2020-2025)
8.6.3 North America Biosimilar Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Biosimilar Revenue (2020-2031)
9.2 Europe Biosimilar Revenue by Type (2020-2031)
9.2.1 Europe Biosimilar Revenue by Type (2020-2025)
9.2.2 Europe Biosimilar Revenue by Type (2026-2031)
9.3 Europe Biosimilar Revenue Share by Type (2020-2031)
9.4 Europe Biosimilar Revenue by Application (2020-2031)
9.4.1 Europe Biosimilar Revenue by Application (2020-2025)
9.4.2 Europe Biosimilar Revenue by Application (2026-2031)
9.5 Europe Biosimilar Revenue Share by Application (2020-2031)
9.6 Europe Biosimilar Revenue by Country
9.6.1 Europe Biosimilar Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Biosimilar Revenue by Country (2020-2025)
9.6.3 Europe Biosimilar Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Biosimilar Revenue (2020-2031)
10.2 China Biosimilar Revenue by Type (2020-2031)
10.2.1 China Biosimilar Revenue by Type (2020-2025)
10.2.2 China Biosimilar Revenue by Type (2026-2031)
10.3 China Biosimilar Revenue Share by Type (2020-2031)
10.4 China Biosimilar Revenue by Application (2020-2031)
10.4.1 China Biosimilar Revenue by Application (2020-2025)
10.4.2 China Biosimilar Revenue by Application (2026-2031)
10.5 China Biosimilar Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Biosimilar Revenue (2020-2031)
11.2 Asia Biosimilar Revenue by Type (2020-2031)
11.2.1 Asia Biosimilar Revenue by Type (2020-2025)
11.2.2 Asia Biosimilar Revenue by Type (2026-2031)
11.3 Asia Biosimilar Revenue Share by Type (2020-2031)
11.4 Asia Biosimilar Revenue by Application (2020-2031)
11.4.1 Asia Biosimilar Revenue by Application (2020-2025)
11.4.2 Asia Biosimilar Revenue by Application (2026-2031)
11.5 Asia Biosimilar Revenue Share by Application (2020-2031)
11.6 Asia Biosimilar Revenue by Country
11.6.1 Asia Biosimilar Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Biosimilar Revenue by Country (2020-2025)
11.6.3 Asia Biosimilar Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Biosimilar Revenue (2020-2031)
12.2 SAMEA Biosimilar Revenue by Type (2020-2031)
12.2.1 SAMEA Biosimilar Revenue by Type (2020-2025)
12.2.2 SAMEA Biosimilar Revenue by Type (2026-2031)
12.3 SAMEA Biosimilar Revenue Share by Type (2020-2031)
12.4 SAMEA Biosimilar Revenue by Application (2020-2031)
12.4.1 SAMEA Biosimilar Revenue by Application (2020-2025)
12.4.2 SAMEA Biosimilar Revenue by Application (2026-2031)
12.5 SAMEA Biosimilar Revenue Share by Application (2020-2031)
12.6 SAMEA Biosimilar Revenue by Country
12.6.1 SAMEA Biosimilar Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Biosimilar Revenue by Country (2020-2025)
12.6.3 SAMEA Biosimilar Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.